PTAB Nixes Seagen Cancer Drug IP After Daiichi Verdict
The Patent Trial and Appeal Board has said Daiichi Sankyo was able to show that the challenged claims of a Seagen cancer drug patent, which a Texas federal jury found Daiichi...To view the full article, register now.
Already a subscriber? Click here to view full article